Keyphrases
177Lu-DOTATATE
100%
Antitumor Activity
100%
Antitumor Efficacy
20%
AR42J Cells
40%
Clinical Evaluation
20%
DNA Damage Repair
20%
DNA Double-strand Breaks
20%
Focus Formation
20%
Growth Properties
20%
Growth Response
20%
In Vitro Study
20%
In Vivo Growth
20%
Neuroendocrine Tumor
40%
Novel Peptide
20%
Novel Therapeutics
20%
PARP Inhibitor (PARPi)
100%
Peptide Receptor Radionuclide Therapy
80%
Radiation-induced DNA Damage
20%
Radionuclide Therapy
100%
Small Molecules
20%
Somatostatin Receptor 2 (SSTR2)
100%
Talazoparib
40%
Therapeutic Action
20%
Therapeutic Combinations
20%
Therapeutic Target
20%
Therapy Efficacy
20%
Therapy Regimen
20%
Treatment Options
20%
Tumor Model
100%
Tumor Regression
20%
γH2AX Foci
20%
Medicine and Dentistry
Antineoplastic Activity
100%
Clinical Trial
16%
DNA Repair
16%
Double-Strand DNA Break
16%
In Vitro
16%
Lutetium 177
100%
Neoplasm
16%
Neuroendocrine Tumor
33%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 1
100%
Oxodotreotide Lu 177
100%
Peptide Receptor
66%
Radionuclide Therapy
100%
Somatostatin Receptor 2
100%
Talazoparib
33%
Tetraxetan
100%
Tumor Model
100%
Tumor Regression
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
16%
Double Stranded DNA
16%
Lutetium 177
100%
Neoplasm
100%
Neuroendocrine Tumor
33%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 1
100%
Oxodotreotide Lu 177
100%
Radioisotope
100%
Receptor
66%
Somatostatin Receptor 2
100%
Talazoparib
33%
Tetraxetan
100%
Tumor Model
100%
Tumor Regression
16%